Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic variation at the CYP2C locus and its association with torsemide biotransformation.

The pharmacogenomics journal - 1 Jun 2007

Vormfelde S V, Schirmer M, Toliat M R, Meineke I, Kirchheiner J, Nürnberg P, Brockmöller J

Abstract excerpt

In 97 unselected volunteers and two additional homozygous carriers of CYP2C9(*)3, we investigated the oral clearance of torsemide in relation to 37 polymorphisms at the CYP2C gene locus. Torsemide total oral clearance was linearly associated with the number of CYP2C9(*)3 alleles (geometric mean: 59, 40 and 20 ml/min in carriers of no, one and two alleles) and so were the methyl- and ring-hydroxylation but not the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Biotransformation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Genotype

Share to Haplotypes

Share to Metabolic Clearance Rate

Share to Polymorphism, Single Nucleotide

Share to Sulfonamides

Source

Identifiers

PMID: 16969365
DOI: 10.1038/sj.tpj.6500410

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variation at the CYP2C locus and its association with torsemide biotransformation.PMID 16969365Read ↗

Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes.Semantic proximity Read ↗

CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide.Semantic proximity Read ↗

Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes.Semantic proximity Read ↗

Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters.Semantic proximity Read ↗

Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers.Semantic proximity Read ↗

Heritability of metoprolol and torsemide pharmacokinetics.Semantic proximity Read ↗

Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5'-hydroxylation.Semantic proximity Read ↗

Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype.Semantic proximity Read ↗

Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.Semantic proximity Read ↗

Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals.Semantic proximity Read ↗

Differential genotype dependent inhibition of CYP2C9 in humans.Semantic proximity Read ↗

Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.